Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 450Stomach Neoplasms 295Rectal Neoplasms 271Colonic Neoplasms 192Pancreatic Neoplasms 177Neoplasm Metastasis 110Esophageal Neoplasms 88Neoplasms 68Carcinoma, Hepatocellular 60Adenocarcinoma Of Esophagus 47Cholangiocarcinoma 46Adenocarcinoma 46Lymphoma, Large B-Cell, Diffuse 44Carcinoma, Non-Small-Cell Lung 41Biliary Tract Neoplasms 38Gallbladder Neoplasms 31Gastrointestinal Neoplasms 29Recurrence 25Liver Neoplasms 25Ovarian Neoplasms 23Esophageal Squamous Cell Carcinoma 23Breast Neoplasms 22Peritoneal Neoplasms 18Bile Duct Neoplasms 17Unspecified Adult Solid Tumor, Protocol Specific 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Locally Advanced Rectal Cancer 13Head and Neck Neoplasms 13Lung Neoplasms 12Lymphoma, Non-Hodgkin 11

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophagogastric Cancer × Oxaliplatin × Clear all
NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡